Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
SPOTLIGHT: Lilly settles 900 more Zyprexa claims
Eli Lilly has settled some 900 lawsuits over its antipsychotic drug Zyprexa, including five set to go to trial next month, leaving about 1,100 claims unsettled. Many of the plaintiffs alleged that Lilly downplayed the drug's side effects, including weight gain and elevated blood sugar. The company has set aside $1.2 billion to cover the claims. Report | Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
